<?xml version="1.0" encoding="UTF-8"?>
<p>In conclusion, the study by Zhao et al indicates that ATC was safe when deployed as first-line therapy in patients with GVHD followed by CMV reactivation. The data further tentatively suggest enhanced recovery of graft-dependent CMV-specific immunity. </p>
